GCOM, EXEL, CPIX - CRWESelect.com Stock News! Globecomm Systems Inc., Exelixis Inc., Cumberland Pharmaceuticals Inc. (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) February 8, 2012 -- To view video, and read the full article visit URL http://crweselect.com/28519/stock-alerts/gcom-exel-cpix-crweselectcom-stock-news-globecomm-systems-inc-exelixis-inc-cumberland-pharmaceuticals-inc-video-included-inside/

Globecomm Systems Inc. (NASDAQ: GCOM)

Revenues for Globecomm Systems Inc. - Symbol GCOM - fiscal 2012 second quarter increased 35.5% to a record $95.2 million as compared to $70.2 million in the same period last year. Revenues from service increased 15.6% to a record $54.7 million, as compared to $47.3 million in the same period last year. Also, revenues for Globecomm Systems Inc. fiscal 2012 six months ended December 31, 2011 increased 34.6% to a record $166.2 million as compared to $123.4 million in the same period last year. Revenues from services increased 16.3% to a record $104.9 million as compared to $90.2 million in the same period last year.

Globecomm Systems Inc., or Globecomm, is a leading global provider of satellite-based managed network solutions. Employing our expertise in emerging communication technologies we are able to offer a comprehensive suite of system integration, system products, and network services enabling a complete end-to-end solution for our customers. We believe our integrated approach of in-house design and engineering expertise combined with a world-class global network and our 24 by 7 network operating centers provides us a unique competitive advantage. We are now taking this value proposition to selective vertical markets, including government, wireless, media, enterprise and maritime. As a network solution provider we leverage our global network to provide customers managed access services to the United States Internet backbone, video content, the public switched telephone network or their corporate headquarters, or government offices. We currently have customers for which we are providing such services in the United States, Europe, South America, Africa, the Middle East, and Asia.

Based in Hauppauge, New York, GCOM also maintains offices in Maryland, New Jersey, Virginia, the Netherlands, South Africa, Hong Kong, Germany, Singapore, the United Arab Emirates and Afghanistan.

For more information about GCOM please visit http://www.globecommsystems.com

****

Exelixis, Inc. (NASDAQ: EXEL)

Exelixis, Inc. - Symbol EXEL - reported today financial results for the fourth quarter and year ended December 31, 2011. Revenues for the fourth quarter ended December 31, 2011 were $93.3 million, compared to $40.8 million for the comparable period in 2010. Revenues for the year ended December 31, 2011 were $289.6 million compared to $185.0 million in 2010.

EXEL is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations.

For more information about EXEL please visit http://www.exelixis.com

****

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)

Cumberland Pharmaceuticals Inc. - Symbol CPIX - announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office relating to its new formulation of Acetadote® (acetylcysteine) Injection, which is used to treat acetaminophen poisoning. The new formulation was FDA approved in 2011 and listed in the "Orange Book," the FDA's official register of approved pharmaceutical products. Once issued, the patent will expire in August 2025.

CPIX is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever available in the United States; and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients.

For more information about CPIX please visit http://www.cumberlandpharma.com

To read the full article visit URL http://crweselect.com/28519/stock-alerts/gcom-exel-cpix-crweselectcom-stock-news-globecomm-systems-inc-exelixis-inc-cumberland-pharmaceuticals-inc-video-included-inside/

*****************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

GCOMcrweselect0208
EXELcrweselect0208
CPIXcrweselect0208

Acetadote     acetaminophen poisoning     CPIX     Cumberland Pharmaceuticals     exel     Exelixis     GCOM     Globecomm Systems